CNTO-5825
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13) . CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis[1].
Product Specifications
UNSPSC
12352203
Target
Interleukin Related
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
[CNTO-5825]
References & Citations
[1]van Hartingsveldt B, et al. Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75 (5) :1289-98.
Shipping Conditions
Dry Ice
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Isoform
IL-13
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
